Moderna (MRNA) reported Q3 earnings Friday of $0.38 per share, swinging from a loss of $0.51 a year earlier.

Analysts polled by FactSet expected a loss of $1.13.

Revenue for the quarter ended Sept. 30 was $1.31 billion, compared with $1.02 billion a year earlier.

Analysts expected $890.3 million.

For 2026, the company now expects revenue growth of 15% to 25%, compared with its prior growth guidance of up to 10%. Analysts are looking for $2.10 billion.

Shares of the company were up 8% in Friday premarket trading.